Patrick Lamy - 10 Jun 2025 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Signature
/s/ Jonathan Young, Attorney-in-Fact
Issuer symbol
AKRO
Transactions as of
10 Jun 2025
Net transactions value
-$49,625
Form type
4
Filing time
12 Jun 2025, 18:32:59 UTC
Previous filing
04 Jun 2025
Next filing
20 Jun 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lamy Patrick Senior VP, Commercial Strategy C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BLVD, SUITE 350, SOUTH SAN FRANCISCO /s/ Jonathan Young, Attorney-in-Fact 12 Jun 2025 0001961273

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Sale $49,625 -919 -2.7% $54.00 32,573 10 Jun 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. Such sales were automatic and not at the discretion of the Reporting Person.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $53.93 to $54.00, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.